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Activated factor IX, factor XI and tissue factor identify 
patients with permanent atrial fibrillation treated with 
warfarin who are at risk of ischemic stroke
Piotr Kusak1, Danuta Czarnecka1, Matthew Gissel2, Krzysztof Plens3, Saulius Butenas2, Anetta Undas1
A b s t r a c t
Introduction: Previously, we have demonstrated that significant proportions 
of patients with various cardiovascular diseases have active tissue factor 
and active factor XIa in their plasma. In the current study, we evaluated 
active tissue factor and active factors (F)XI and FIX in plasma from patients 
with atrial fibrillation. 
Material and methods: In 110 consecutive patients with permanent atrial 
fibrillation receiving warfarin, we determined active tissue factor, together 
with plasma FIXa and FXIa, using clotting assays by measuring the response 
to inhibitory monoclonal antibodies.  
Results: Sixteen (14.5%) patients had detectable active tissue factor and ac-
tive FXIa, including 11 subjects with both factors, while FIXa was observed in 
28 (25.7%) patients. The three positive groups did not differ from the patients 
without these factors with regard to demographic and clinical characteristics. 
Von Willebrand factor was higher in the active tissue factor-positive group 
(p < 0.0001) and FXIa-positive group (p = 0.0037). Individuals positive for ac-
tive tissue factor and FXIa had higher plasma interleukin-6 levels (p = 0.0014 
and 0.0322, respectively). The presence of active tissue factor, FXIa and FIXa 
in anticoagulated patients with permanent atrial fibrillation correlated with 
elevated von Willebrand factor and interleukin-6. During a 3-year follow-up, 
ischemic stroke (n = 12, 10.9%) occurred more commonly among atrial fibril-
lation patients who had circulating TF (p = 0.002) or FXIa (p = 0.013). 
Conclusions: These data suggest that circulating active coagulation factors, 
in particular TF and FXIa, can be detected despite oral anticoagulation in 
a significant proportion of patients with atrial fibrillation, and could repre-
sent novel markers of persistent prothrombotic alterations predisposing to 
ischemic stroke.
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Introduction
Atrial fibrillation (AF) is associated with a prothrombotic state and an 
increased risk of thromboembolic complications [1, 2]. Mechanisms un-
derlying hypercoagulability in AF are complex and involve hemodynam-
ic changes, endothelial damage reflected by increased von Willebrand 
factor (VWF) antigen, enhanced platelet activation reflected by elevated 
circulating levels of β-thromboglobulin [3] and P-selectin [4], increased 
Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk 
of ischemic stroke
Arch Med Sci 5, October / 2016 1001
thrombin generation [3] and plasma fibrinogen 
[4], and impaired efficiency of plasma fibrin clot ly-
sis [5]. A coexistent low-grade inflammatory state, 
reflected by elevated C-reactive protein (CRP) and 
interleukin-6 (IL-6), contributes to AF and can 
promote atrial remodeling, recurrence and per-
sistence of arrhythmia [6].
Tissue factor (TF) is a  major trigger of blood 
coagulation in vivo. The complex of TF with fac-
tor VIIa (FVIIa) activates factor IX (FIX) and factor 
X (FX), leading to thrombin formation. It is sug-
gested that TF is expressed in some pathological 
states on monocytes probably due to inflamma-
tion [7, 8]. It has been reported that circulating 
plasma TF concentrations are elevated in patients 
with arterial hypertension, hypercholesterolemia, 
diabetes or coronary artery disease [9–11], but 
this issue is still controversial [8]. 
Factor XIa (FXIa) is involved in the intrinsic 
coagulation pathway. The activation of factor XI 
(FXI), which occurs primarily by thrombin, leads to 
FIX and FX activation. Elevated FXIa has been im-
plicated in prothrombotic states observed in acute 
coronary syndromes [9, 12], stable angina [13] and 
heart failure [12].
FIX can be activated by FXIa and the FVIIa/TF 
complex [14]. The activation of FX by the intrinsic 
factor Xase complex (FIXa bound to its cofactor, 
factor VIIIa) makes FIXa a potential marker of hy-
percoagulability. Increased FIXa activity has been 
observed in acute coronary syndromes [15]. To 
our knowledge, no reports have been published 
on FIXa or FXIa in AF patients.
The role of TF, FXIa and FIXa as prognostic mark-
ers is unclear. In patients with prior ischemic stroke 
(regardless of etiology), the presence of TF and FXIa 
is associated with worse prognosis [16]. Chin et al. 
reported that elevated circulating TF is a  marker 
of poor prognosis in heart failure [17]. Given the 
marked differences in assays used to quantify TF 
in circulating blood, determination of active TF 
usually indicates much less common prevalence of 
detectable levels of this factor in plasma.
To the best of our knowledge, TF, FXIa and FIXa 
assessed using coagulometric assays have not 
been determined in AF, and factors that influence 
plasma levels of these proteins remain obscure. 
We decided to verify the working hypothesis that 
the presence of circulating TF, FIXa and FXIa in AF, 
if detectable in anticoagulated subjects, might 
help identify persistent prothrombotic alterations 
in such a population. In the present study, we de-
termined TF activity, FXIa and FIXa together with 
their associations with inflammatory and endo-
thelial injury markers in patients with permanent 
AF. We tested the hypothesis that the presence of 
circulating TF, FIXa and/or FXIa in AF despite anti-
coagulant therapy predisposes to ischemic stroke.
Material and methods
Study population
We studied 110 consecutive patients with 
permanent AF receiving oral anticoagulation 
with warfarin for more than 1 year after having 
screened 170 individuals with the time in the 
therapeutic range above 70% in the last year. We 
excluded patients with acute coronary syndrome 
within the preceding 6 months, heart failure 
(NYHA III/IV), hepatic dysfunction, chronic renal 
disease above level 3 (glomerular filtration rate 
less than 60 ml/min/1.73 m2), history of venous 
thromboembolism or stroke, acute illness, can-
cer, and those who underwent surgery within the 
preceding month – all the conditions associated 
with increased thrombin generation. Coronary 
artery disease (CAD) was defined as a history of 
myocardial infarction, coronary revascularization, 
or hospitalization for unstable angina. Diabetes 
was diagnosed according to the World Health Or-
ganization criteria. Hypercholesterolemia was de-
fined as total cholesterol > 5 mmol/l, or low-den-
sity lipoprotein (LDL) cholesterol > 3.0 mmol/l or 
treatment with cholesterol-lowering medication. 
Arterial hypertension was defined according to 
a standard definition, i.e. systolic or diastolic pres-
sure ≥ 140 mm Hg or ≥ 90 mm Hg, respectively, 
on at least two different measurements, previous 
history of hypertension or current antihyperten-
sive treatment. Heart failure was diagnosed in 
subjects with decreased left ventricular ejection 
fraction (LVEF) < 50% on echocardiography. Trans-
thoracic echocardiography was performed in each 
patient using conventional techniques to measure 
the left atrial diameter and LVEF.
A 3-year follow-up started at the time of enroll-
ment and was carried out on a 6-month basis by 
means of a visit to the center or telephone contact. 
None of the patients declared any interruption of 
warfarin use for more than 7 days. We recorded 
the objectively documented ischemic stroke.
The study was approved by the Ethical Com-
mittee, and all patients provided written informed 
consent.
Laboratory methods
Blood was drawn from an antecubital vein with 
minimal stasis after an overnight fast between 
7 and 9 a.m. Serum and citrate plasma samples 
(9 : 1 of 3.2% sodium citrate) were centrifuged at 
2,540 g for 15 min at 24°C within 20 min of col-
lection, immediately frozen, and stored in aliquots 
at –80°C until further use. Lipid profiles, blood 
cell counts, glucose, creatinine, and International 
Normalized Ratio (INR) were assayed by routine 
laboratory techniques. High-sensitivity CRP was 
measured by latex nephelometry (Dade Behring, 
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Marburg, Germany). Commercially available im-
munoenzymatic assays were used to determine 
plasma IL-6 (R&D Systems, Abingdon, UK) and 
VWF antigen (Diagnostica Stago, Asnieres, France). 
All intra-assay and inter-assay coefficients of vari-
ation were below 7%.
Plasma clotting assays
Plasma was thawed at 37ºC in the presence of 
0.1 mg/ml corn trypsin inhibitor (CTI; prepared as 
previously described) [18]. CaCl2 to a final 15 mM 
concentration was added and the plasma incubat-
ed for 1 min; clotting was initiated by the addition 
of 2 μM phospholipid vesicles (PCPS) composed of 
25% dioleoyl-sn-glycero-3-phospho-L-serine and 
75% of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(both from Avanti Polar Lipids, Inc; Alabaster, AL, 
USA) and prepared as described previously [19]. 
In parallel, inhibitory monoclonal anti-FXI (αFXI-2), 
anti-FIX (αFIX-91) or anti-TF (αTF-5) antibodies 
(both produced in house) at a final 0.1 mg/ml con-
centration were individually added to the same 
plasma prior to CaCl2 addition. αFXI-2 is specific 
for FXI/XIa and inhibits FIX activation by FXIa [20]. 
αTF-5 binds specifically to TF and interferes with 
TF/FVIIa complex formation [21]. Clotting times 
were determined using the ST8 instrument (Di-
agnostica Stago, Parsippany, NJ, USA). FXIa, FIXa 
and TF activity in plasma was calculated from 
calibration curves developed with human FIXa or 
FXIa (gifts from Dr. R. Jenny from Haematologic 
Technologies, Inc., Essex Junction, VT, USA) or re-
lipidated [18] TF1–243 (a  gift from Dr. R. Lundblad 
from Baxter Healthcare Corp., Duarte, CA, USA) in 
pooled 10-donor normal plasma. The detectability 
limit for TF was 0.4 pM, for FXIa 10 pM, and for 
FIXa 100 pM. In 12 healthy subjects all the 3 pa-
rameters were undetectable.
Statistical analysis
Due to skewness of most variables, continuous 
variables are presented as median and quartiles. 
Categorical variables are presented as numbers 
and percentages. To examine differences between 
two independent groups, the Mann-Whitney test, 
Welch’s t-test or the pooled t-test was used de-
pending on normality of distributions and equal-
ity of variances of groups. The Fisher exact test 
was used to compare categorical variables. Odds 
ratios with 95% confidence intervals were com-
puted using a  logistic regression model with the 
presence of TF or FXIa or FIXa (composite vari-
able) as the dependent variable [22, 23]. The same 
method was performed to calculate stroke predic-
tors. Two-sided p-values < 0.05 were considered 
statistically significant. Statistical analysis was 
performed with the use of JMP 9.0.0.
Results
Patient characteristics are presented in Table I. 
The study population was divided into groups 
with or without the specific coagulation factors, 
i.e.: TF(+) and TF(–), FXIa(+) and FXIa(–), FIXa(+) 
and FIXa(–). Age, prevalence of coronary artery 
disease, diabetes mellitus, heart failure, CHA2DS2-
VASc score along with cholesterol, glucose, creat-
inine, INR, and CRP were similar in the TF(+) and 
TF(–) group, the FXIa(+) and FXIa(–) group, and the 
FIXa(+) and FIXa(–) group. 
Tissue factor – 16 (14.5%) patients had detect-
able TF and the median value for only those who 
have > 0.4 pM TF was 1.17 pM (IQR: 0.43–2.19). 
Arterial hypertension was less common in the 
TF(+) group as compared to the TF(–) group. The 
proportion of current smokers was lower in the 
TF(+) group. In the CHADS2 score, fewer patients 
had 1 point in the TF(+) group. Higher levels of 
VWF (+31.0%) and IL-6 (+40.1%) were observed 
in the TF(+) group compared with the TF(–) group. 
CRP was similar in both groups (Table I).
Factor XIa – 16 (14.5%) participants had mea-
surable FXIa (median 77.98 pM, IQR: 30.79–
170.08). Both TF and FXIa were observed in 11 
(10%) subjects. Current smokers was less fre-
quently observed in the FXIa(+) group. Fewer indi-
viduals in the FXIa(+) group had one point in the 
CHADS2 score. VWF (+18.7%) and IL-6 (+21.3%) 
were higher in the FXIa(+) group compared with 
the FXIa(–) group. CRP was similar in both groups 
(Table I).
Factor IXa (FIXa) was observed in 28 (25.5%) 
patients with a median value of 592.4 pM (IQR: 
209.0–1032.5). None of the patients had FIXa in 
combination with both TF and FXIa. Males were 
more prevalent in the FIXa(+) group. Body mass in-
dex (BMI) was higher in the FIXa(+) group. A simi-
lar proportion of patients had 2 or more points in 
the CHADS2 score. IL-6, VWF and CRP were similar 
in both groups (Table I).
The univariate logistic regression showed that 
a higher risk of the presence of one of the tested 
factors (TF, FIXa or FXIa) was observed in patients 
with coronary artery disease (OR = 6.27; 95% CI: 
1.85–28.9). Higher VWF (OR = 1.15; 95% CI: 1.05–
1.27) and IL-6 (OR = 1.29; 95% CI: 1.05–1.61) were 
also associated with a higher risk of presence of 
one of the tested coagulation factors (Figure 1). 
Stroke – During a 3-year follow-up we recorded 
12 (10.9%) patients with ischemic stroke. No ma-
jor bleeding events were observed; 10 patients had 
clinically relevant bleeding mostly from the gastro-
intestinal tract. The prevalence of stroke was high-
er in patients with diabetes, heart failure and in 
patients with two or more points in the CHADS2 
score (Table II). Higher levels of VWF (+18.4%), 
D-dimer (+51.1%), and fibrinogen (+27.4%) were 
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Table I. Characteristics of patients with chronic atrial fibrillation
Variable N = 110 TF(+)
n = 16
TF(–)
n = 94
FXIa(+)
n = 16
FXIa(–)
n = 94
FIXa(+) 
n = 28
FIXa(–)
n = 81
Age [years] 63.0  
(55.0; 70.0)
60.0  
(52.0; 67.8)
63.0  
(56.0; 70.3)
57.0  
(50.3; 69.8)
63.5  
(56.8; 70.0)
61.5  
(53.3; 66.8)
64.0  
(55.0; 71.5)
Male gender,  
n (%)
57 (51.8) 8 (50.0) 49 (52.1) 7 (43.8) 50 (53.2) 20 (71.4)* 37 (45.7)
BMI [kg/m2] 29.1  
(26.6; 31.4)
30.7  
(26.9; 32.2)
29.0  
(26.3; 31.2)
27.1  
(25.1; 32.0)
29.2  
(26.8; 31.2)
31.8  
(26.4; 35.5)*
28.4  
(26.6; 30.6)
Hypertension, 
n (%)
65 (59.1) 4 (25.0)* 61 (64.9) 6 (37.5) 59 (62.8) 19 (67.9) 46 (56.8)
CAD, n (%) 15 (13.6) 3 (18.8) 12 (12.8) 4 (25.0) 11 (11.7) 7 (25.0) 8 (9.9)
Diabetes,  
n (%)
6 (5.5) 2 (12.5) 4 (4.3) 2 (12.5) 4 (4.3) 1 (3.6) 5 (6.2)
Heart failure,  
n (%)
20 (18.2) 1 (6.3) 19 (20.2) 1 (6.3) 19 (20.2) 7 (25.0) 13 (16.0)
Smoking,  
n (%)
44 (40.0) 2 (12.5)* 42 (44.7) 2 (12.5)* 42 (44.7) 10 (35.7) 34 (42.0)
CHADS2
≥ 2 points
27 (24.5) 3 (18.8) 25 (25.5) 4 (25.0) 23 (24.5) 7 (25.0) 20 (24.7)
CHADS2
1 point
47 (42.7) 2 (12.5)* 45 (47.9) 2 (12.5)* 45 (47.9) 15 (53.6) 32 (39.5)
CHA2DS2-VASc
≥ 2 points, 
n (%)
64 (58.2) 5 (31.3)* 59 (62.8) 6 (37.5) 58 (61.7) 16 (57.1) 48 (59.3)
CHA2DS2-VASc
1 point, n (%)
37 (33.6) 9 (56.3)* 28 (29.8) 8 (50.0) 29 (30.9) 9 (32.1) 27 (33.3)
Aspirin, n (%) 35 (31.8) 9 (56.2)* 26 (27.7) 12 (75.0)* 23 (24.5) 12 (42.9) 22 (27.2)
Statin, n (%) 53 (48.2) 1 (6.3)* 52 (55.3) 4 (25.0) 49 (52.1) 10 (35.7) 43 (53.1)
Total 
cholesterol 
[mM]
5.05  
(4.17; 5.62)
5.01  
(4.62; 5.89)
5.05  
(4.01; 5.61)
4.83  
(4.05; 5.49)
5.08  
(4.18; 5.65)
5.25  
(3.91; 5.87)
5.03  
(4.19; 5.59)
LDL 
cholesterol 
[mM]
2.91  
(2.36; 3.40)
3.02  
(2.51; 3.38)
2.86  
(2.36; 3.40)
3.00  
(2.34; 3.10)
2.86  
(2.38; 3.43)
2.95  
(2.22; 3.79)
2.88  
(2.41; 3.36)
HDL 
cholesterol 
[mM]
1.46  
(1.14; 1.70)
1.61  
(1.21; 1.74)
1.44  
(1.14; 1.69)
1.56  
(1.00; 1.69)
1.45  
(1.18; 1.71)
1.46  
(1.15; 1.72)
1.45  
(1.14; 1.70)
Triglycerides 
[mM]
1.15  
(0.74; 1.66)
1.43  
(0.64; 1.93)
1.13  
(0.75; 1.58)
1.17  
(0.62; 1.67)
1.13  
(0.75; 1.66)
0.94  
(0.67; 1.63)
1.17  
(0.78; 1.69)
Glucose  
[mM]
4.90  
(4.50; 5.20)
4.95  
(4.53; 5.40)
4.87  
(4.50; 5.20)
4.85  
(4.43; 5.30)
4.90  
(4.51; 5.20)
4.85  
(4.43; 5.08)
4.90  
(4.51; 5.25)
Creatinine 
[μM]
70.7  
(60.8; 80.3)
72.5  
(58.0; 85.8)
70.7  
(61.0; 79.7)
62.5  
(50.8; 84.0)
70.7  
(61.9; 80.3)
69.5  
(60.0; 79.8)
69.5  
(60.0; 79.8); 
INR 2.48  
(2.25; 2.83)
2.50  
(2.20; 2.78)
2.45  
(2.25; 2.84)
2.60  
(2.39; 2.92)
2.44  
(2.20; 2.75)
2.40  
(2.08; 2.72)
2.49  
(2.30; 2.85)
VWF (%) 210.5  
(169.0; 240.3)
271.0  
(251.0; 279.0)*
196.5  
(168.0; 231.3)
253.0  
(192.8; 278.8)*
 205.5  
(168.0; 235.3)
222.0  
(168.5; 235.8)
 202.0  
(169.0; 245.5)
CRP [mg/l] 2.96  
(1.89; 4.44)
2.35  
(1.20; 4.13)
3.01  
(1.92; 4.70)
2.23  
(1.20; 4.13)
3.01  
(1.98; 4.51)
3.12  
(2.08; 5.29)
2.98  
(1.83; 4.42)
IL-6 [pg/ml] 5.55  
(4.40; 7.03)
7.65  
(5.50; 9.88)*
5.40  
(4.30; 6.70)
6.30  
(5.30; 9.33)*
5.40  
(4.30; 6.83)
5.40  
(4.23; 7.08)
5.60  
(4.45; 6.75)
LVEF (%) 49.0  
(41.2; 55.0)
52.1  
(41.5; 59.7)
47.9  
(40.9; 55.0)
53.0  
(43.3; 59.7)
47.9  
(40.4; 55.0)
51.0  
(42.4; 57.9)
48.0  
(40.8; 53.4)
LA [mm] 43.0  
(40.0; 46.0)
44.5  
(42.3; 52.8)*
43.0  
(40.0; 45.0)
42.5  
(38.5; 44.8)
43.0  
(40.0; 46.0)
43.5  
(40.0; 47.0)
43.0  
(40.5; 45.0)
Values are presented as median and quartiles or as percentages. *Values of p < 0.05 versus a subgroup without the factor tested.
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observed in patients who experienced stroke. As 
expected, time in therapeutic range (TTR) (–27.4%) 
was lower in patients with stroke (Table II). Impor-
tantly, TF and FXIa were present more commonly 
among the patients with stroke despite warfarin 
use (OR = 8.80, 95% CI: 2.36–33.67, and OR = 5.65, 
95% CI: 1.46–21.02, respectively) (Figure 2). FIXa 
tended to be more prevalent among patients with 
stroke (p = 0.07) (Table II). In the multivariate logis-
tic regression model the independent predictors of 
stroke in AF patients while on warfarin were heart 
failure, treatment with angiotensin-converting en-
zyme inhibitor (ACEI) and the presence of active TF 
after adjustment for TTR. 
Discussion
Our data indicate that TF, FXIa and FIXa are ob-
served in a  substantial proportion of anticoagu-
lated AF patients. Permanent AF per se is a patho-
logical state in which despite warfarin therapy 
enhanced blood coagulation reflected by the pres-
ence of active TF, FXIa and FIXa can be observed. 
The appearance of these factors is independent 
from INR values. Butenas et al. showed that CAD 
leads to increased levels of plasma active TF and 
FXIa and inflammatory cytokines are involved in 
this phenomenon [9]. In hypertensive individuals 
higher TF [10] and FIXa [24] have been observed. 
AF itself, being a hypercoagulable state, in associ-
ation with diabetes enhances prothrombotic alter-
ations, because it is known that diabetes is char-
acterized by increased amounts of circulating TF, 
fibrinogen, and thrombin formation markers [25–
27]. In search for determinants of the presence of 
active TF, FXI and FIXa in AF patients, we found 
that CAD is associated with the presence of one 
of the tested factors. One might speculate that 
this factor may contribute to the progression of 
this disease. We failed to observe any correlation 
between the three factors and diabetes. Unex-
pectedly, in the TF(+) group, hypertensive patients 
were underrepresented compared with the TF(–) 
group. Hypercholesterolemia has been suggested 
to induce TF expression, and statin treatment may 
reduce active TF in circulating blood [11, 28]. In 
our study, a substantial proportion of AF patients 
without TF were treated with statins. However, it 
should be stressed that statin intake characteriz-
es patients at higher cardiovascular and throm-
boembolic risk. A novel finding is an association 
of VWF with the presence of active TF and FXIa 
in AF patients. Increased plasma VWF that results 
Figure 1. Univariate logistic regression analyses for the presence of active tissue factor (TF), activated factor XI 
(FXIa) or factor IX (FIXa). Detection of TF, FIXa or FXIa in anticoagulated patients with permanent atrial fibrillation 
is predicted by elevated vWF, IL-6, CAD, use of ACEI and/or aspirin, while current smoking and statin use are asso-
ciated with the absence of any of these factors in circulating blood
The graph with logarithmic scale shows point estimates of odds ratios with 95% confidence intervals. vWF – von Willebrand 
factor, IL-6 – interleukin-6, CAD – coronary artery disease, ASA – aspirin, ACEI – angiotensin-converting enzyme inhibitor,  
F – factor. *p < 0.05.
Age per 10 years
0.84 (0.58; 1.21)
p = 0.3437
Male Y/N
1.99 (0.93; 4.32)
p = 0.0759
VWF per 10%
1.15 (1.05; 1.27)
p = 0.0015*
IL-6 per 1 pg/ml
1.29 (1.05; 1.61)
p = 0.0133*
Smoking Y/N
0.35 (0.15; 0.77)
p = 0.0090*
CAD Y/N
6.27 (1.85; 28.88)
p = 0.0025*
ACEI Y/N
7.49 (3.06; 20.05)
p < 0.0001*
ASA Y/N
5.31 (2.26; 13.29)
p < 0.0001*
Statin Y/N
0.23 (0.10; 0.50)
p = 0.0002*
Hypertension Y/N
0.64 (0.29; 1.37)
p = 0.2491
 0 Favours TF(–), FXIa(–) and FIX(–) 1 Favours TF(+), FXIa(+) and FIX(+) 10
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Figure 2. Univariate logistic regression analyses for ischemic stroke in anticoagulated patients with permanent 
atrial fibrillation during follow-up. Stroke is associated with the use of ACEI, higher CHADS2 score, vWF, D-dimer, 
fibrinogen, coexisting diabetes type 2 or heart failure, and detection of TF, or FXIa at enrolment. Only higher TTR is 
associated with low stroke risk
The graph with logarithmic scale shows point estimates of odds ratios with 95% confidence intervals. ACEI – angiotensin-
converting enzyme inhibitor, vWF – von Willebrand factor, LA – left atrium size, TTR – time in therapeutic range, F – factor.  
*p < 0.05.
ACEI Y/N
8.76 (2.40; 41.87)
p = 0.0008*
CHADS2 per 1 point
2.55 (1.21; 5.77)
p = 0.0131*
VWF per 10%
1.24 (1.06; 1.48)
p = 0.0045*
LA per 1 mm
1.14 (1.01; 1.30)
p = 0.0395*
TTR per 10%
0.37 (0.20; 0.59)
p < 0.0001*
D-dimer per 50 ng/ml
1.71 (1.27; 2.42)
p = 0.0003*
Fibrinogen per 1 g/l
1.55 (1.03; 2.46)
p = 0.0338*
FIXa present Y/N
3.41 (0.98; 11.95)
p = 0.0541*
FXIa present Y/N
5.65 (1.46; 21.02)
p = 0.0134*
TF present Y/N
8.80 (2.36; 33.67)
p = 0.0016*
Heart failure Y/N
6.00 (1.67; 21.90)
p = 0.0069*
Diabetes Y/N
10.56 (1.74; 65.03)
p = 0.0124*
Male Y/N
0.63 (0.18; 2.11)
p = 0.4555
 0 Favours stroke absence 1 Favours stroke presence 20
Table II. Characteristics of atrial fibrillation patients with and without stroke incidence during 3-year follow-up
Variable Stroke P-value
Absent (N = 98, 89.1%) Present (N = 12, 10.9%)
Diabetes, n (%) 3 (3.1) 3 (25.0) 0.017
Heart failure, n (%) 14 (14.3) 6 (50.0) 0.008
ACEI, n (%) 25 (25.5) 9 (75.0) 0.001
Fibrinogen [g/l] 4.00 (2.38; 4.83) 4.38 (3.91; 5.16) 0.04
VWF (%) 201.5 (168.0; 236.8) 238.5 (210.8; 278.0) 0.006
D-dimer [ng/ml] 215.0 (154.8; 277.5) 317.0 (287.5; 404.0) 0.0001
TF present, n (%) 10 (10.2) 6 (50.0) 0.002
FXIa present, n (%) 11 (11.2) 5 (41.7) 0.015
FIXa present, n (%) 22 (22.7) 6 (50.0) 0.073
FIXa, FXIa or TF present, n (%) 37 (37.8) 12 (100) < 0.0001
Time in therapeutic range (%) 75.0 (65.0; 85.0) 55.0 (45.0; 60.0) < 0.0001
CHADS2
1 point, n (%)
47 (48.0) 0 (0.0) 0.0011
CHADS2
≥ 2 points, n (%)
18 (18.4) 9 (75.0) 0.0001
Abbreviations see Table I. ACEI – angiotensin-converting enzyme inhibitor. 
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from endothelial damage has been demonstrated 
to predict cardiovascular events including stroke 
in AF [29]. It originates from damaged endothe-
lial cells but in AF mostly from atrial endothelial 
cells [30]. The current findings provide additional 
evidence that there is a correlation between en-
dothelial dysfunction and prothrombotic state re-
flected by the activity of TF and FXI in AF and this 
link is present despite oral anticoagulation. 
Our data showed that IL-6 was higher in anti-
coagulated AF patients with detectable TF or FXIa. 
It is well known that inflammation is associated 
with AF, and ongoing inflammation can predispose 
to AF. Moreover, structural heart diseases can pro-
mote inflammation, and inflammatory markers 
are increased in this arrhythmia [31–33]. Since 
IL-6 failed to be shown as an independent predic-
tor of the presence of TF or FXIa in our patients, it 
might be speculated that in permanent AF during 
warfarin administration inflammation has a  mi-
nor effect on the generation and persistence of 
active TF and FXIa. 
To our knowledge, our study is the first to show 
the presence of circulating plasma FIXa in chronic 
AF and characterizes factors associated with the 
presence of circulating TF or FXIa. The current 
study suggests that regulation of FIXa formation 
and persistence in circulating blood differ from 
the mechanisms and associations observed for 
active TF and FXIa in AF patients. Due to the pau-
city of data on FIXa in the plasma of cardiovas-
cular patients, its role in blood coagulation merits 
further investigations.
We observed that stroke occurs more common-
ly among anticoagulated AF patients who had 
circulating TF and FXIa at enrollment. This novel 
finding suggests that the two coagulation factors 
present on warfarin, together with low quality of 
anticoagulation, heart failure and diabetes, pre-
dispose to ischemic complications of AF during 
follow-up. Larger studies are needed to validate 
this observation.
Several study limitations should be acknowl-
edged. The small number of the patients studied 
especially in subgroups hampers the data inter-
pretation. A  larger cohort is needed to confirm 
our observations. There was no control ‘disease’ 
group with sinus rhythm; therefore we cannot ex-
clude a potential impact of coexisting cardiovas-
cular diseases or medications on the presence of 
circulating TF, FXIa or FIXa. Since transesophageal 
echocardiography was not performed, we can-
not exclude the presence of a  thrombus within 
the left atrium appendage, which might increase 
hypercoagulability including circulating TF. Long-
term follow-up with clinical outcomes is needed 
to evaluate the potential predictive value of active 
TF, FXIa, or FIXa in thromboembolic risk associated 
with permanent AF. It remains to be established 
whether new oral thrombin and FXa inhibitors, 
which are now widely used in AF, can more effec-
tively suppress formation of active TF, FXIa, and 
FIXa [34, 35]. A role of these factors, particularly TF, 
cannot be ruled out also in other cardiovascular 
diseases, e.g. abdominal aneurysm [36].
In conclusion, the present study showed the 
presence of TF, FXIa and FIXa in anticoagulated pa-
tients with permanent AF. VWF and IL-6 have been 
identified as laboratory determinants of the pres-
ence of those active coagulation factors in this AF 
patient population despite anticoagulation. It is 
tempting to speculate that TF, FXIa and FIXa might 
be considered as novel markers of thromboembol-
ic risk in AF, which can be detected even during 
warfarin therapy. 
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